|
Quadruple Therapy Unaffordable for Many HFrEF Patients on Medicare
|
|
Clinical guidelines are increasingly urging quadruple therapy to treat patients with heart failure with reduced ejection fraction (HFrEF). The problem is that the use of medications from four different classes is essentially unaffordable for many Medicare beneficiaries. A new study led by Yale School of Medicine researchers lays out the problem and possible solutions. Read more.
|
|
|
Insufficient Exposure to Paxlovid Causes Rebound COVID-19 Symptoms
|
|
|
What is causing rebound COVID-19 symptoms in some patients treated with Paxlovid? A new study suggests the problem is insufficient exposure to the drug, not impaired immunity against the virus or resistance to Paxlovid. The authors suggest the situation would be improved if prescribers could test whether patients might require a longer duration of Paxlovid treatment or might be best treated by a combination of drugs. Read more.
|
|
No Proof of Vitamin, Supplement Effectiveness Despite Use
|
|
|
Vitamins and supplements are used by most adults in the United States and make up a nearly $50 billion market. However, a national advisory panel still can find no evidence that they are effective in preventing cardiovascular disease or cancer in healthy adults. In some cases, researchers suggested that specific products can be harmful. Learn more about which ones.
|
|
|
Pharmacy Groups Want PREP Act to Remain in Place
|
|
The Public Readiness and Emergency Preparedness (PREP) Act, put in place to respond to the COVID-19 pandemic, has allowed pharmacists and pharmacy staff to play a central role in administering vaccines and performing other duties that have saved lives in recent years. Now, more than 90 key pharmacy and public health groups are asking that it be extended until October 2024. Read more.
|
|
.jpg)
